ROS-responsive bionanodrug for atherosclerosis therapy via regulating glycolipid metabolism and cell crosstalk
Journal of Controlled Release · 2026-11 · 399 · 115362
DOI: 10.1016/j.jconrel.2026.115362 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-11. Verfasst von Jie Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan 750004, China; Ningxia Key Laboratory of Vascu…. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Atherosclerosis, Glycolipids, Rosuvastatin Calcium. Die Arbeit nennt 58 Literaturangaben. Gefördert von: National Science and Technology Major Project, Ningxia Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Atherosclerosis (AS) is a long-term inflammatory disorder marked by dysfunctional glycolipid metabolism, abnormal inflammatory response and intercellular crosstalk. Rosuvastatin (RSV), a first-line drug with lipid-lowering activity, fails to adequately modulate the inflammatory microenvironment of atherosclerotic plaques. The natural active ingredient shikonin (SKN) compensates for this limitation through inhibiting glycolysis and anti-inflammation. However, how to efficiently co-delivery them to the plaques remains challenging. In this study, we engineered a ROS-responsive nanosystem (TK-MLP@SR NPs) containing SKN and RSV. This system enables drug release in the plaque microenvironment with high ROS levels, prolongs circulation time, and achieves active lesion targeting. In vitro assay indicated the function of TK-MLP@SR NPs for inhibiting glycolysis and promoting fatty acid oxidation (FAO) in homocysteine-treated macrophages, thereby inhibiting foam cell formation and alleviating inflammation. Moreover, this nanosystem inhibited phenotype switch of vascular smooth muscle cell by restoring normal macrophage - smooth muscle cell crosstalk. In ApoE-/- mice, the accumulation of TK-MLP@SR NPs in the plaque reduced macrophage infiltration, thereby modulating the inflammatory microenvironment to restore smooth muscle cell function and improve the plaque stability, characterized by less lipid deposition, and increased collagen, along with smaller necrotic cores. Compared with free drugs, this strategy exhibited superior efficacy in regulating the plaque microenvironment by inhibiting lipid deposition. In summary, this work introduces a novel plaque environment-activated prodrug platform, providing valuable insights for clinical translation of AS therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan 750004, China; Ningxia Key Laboratory of Vascular Injury and Repair Research, Yinchuan 750004, China.
- NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan 750004, China; School of Basic Medical Sciences, Ningxia Medical University, Yinchuan 750004, China.
- College of Biology, Hunan University, Changsha 410082, China.
- Medical Experimental Center, General Hospital of Ningxia Medical University, Yinchuan 750004, China; Department of Medical Genetics, Hunan Provincial Maternal and Child Health Hospital, Changsha 410008, China.
- NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan 750004, China; College of Biology, Hunan University, Changsha 410082, China. Electronic address: binliu2001@hotmail.…
- NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Ningxia Medical University, Yinchuan 750004, China; Ningxia Key Laboratory of Vascular Injury and Repair Research, Yinchuan 750004, China; School of Basi…
Förderung
- National Science and Technology Major Project
- Ningxia Medical University
- National Natural Science Foundation of China
Zitieren
APA
Yu, J., Dong, X., Yu, F., Wu, Y., Wang, X., Zhang, H., Liu, B., & Jiang, Y. (2026). ROS-responsive bionanodrug for atherosclerosis therapy via regulating glycolipid metabolism and cell crosstalk. Journal of Controlled Release, 399, 115362. https://doi.org/10.1016/j.jconrel.2026.115362
Vancouver
Yu J, Dong X, Yu F, Wu Y, Wang X, Zhang H, et al. ROS-responsive bionanodrug for atherosclerosis therapy via regulating glycolipid metabolism and cell crosstalk. Journal of Controlled Release. 2026;399:115362. doi:10.1016/j.jconrel.2026.115362
BibTeX
@article{Yu2026,
author = {Yu, Jie and Dong, Xiaoyan and Yu, Feifei and Wu, Yizhou and Wang, Xue and Zhang, Huiping and Liu, Bin and Jiang, Yideng},
title = {ROS-responsive bionanodrug for atherosclerosis therapy via regulating glycolipid metabolism and cell crosstalk},
journal = {Journal of Controlled Release},
year = {2026},
volume = {399},
pages = {115362},
doi = {10.1016/j.jconrel.2026.115362}
}
EUVIMED